Guy's And ST Thomas' NHS Foundation Trust
- Country
- 🇬🇧United Kingdom
- Ownership
- -
- Established
- 1993-01-01
- Employees
- 25
- Market Cap
- -
Clinical Trials
335
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (205 trials with phase data)• Click on a phase to view related trials
MultIple Long-term Conditions in Pregnancy and Experiences of Midwifery Care
- Conditions
- How Pregnant and Postnatal Women With Two or More Long-term Health Conditions Experience Midwifery Care as Part of Multi-disciplinary Maternity Care
- First Posted Date
- 2025-10-06
- Last Posted Date
- 2025-10-06
- Lead Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Target Recruit Count
- 80
- Registration Number
- NCT07207759
Inflammation-resolution Therapy in MINST of Periodontal Intrabony Defect: a Pilot Randomised Controlled Trial
- Conditions
- Periodontal DiseasesPeriodontitis
- First Posted Date
- 2025-10-02
- Last Posted Date
- 2025-10-02
- Lead Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Target Recruit Count
- 20
- Registration Number
- NCT07203872
- Locations
- 🇬🇧
Oral Clinical Research Unit (OCRU) at King's College London (KCL), London, United Kingdom
Exploring if Patients Can Safely and Easily Swab Their Own Surgical Wounds at Home
- Conditions
- Cardiac SurgeryInfection, Soft TissueWound HealingSwabsSelf Management
- First Posted Date
- 2025-10-01
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Target Recruit Count
- 40
- Registration Number
- NCT07200401
- Locations
- 🇬🇧
Royal Sussex County Hospital, Brighton, United Kingdom
🇬🇧Harefield Hospital, Harefield, United Kingdom
Optimising the Delivery of Diabetes Distress Informed Care for Its Prevention, Detection, and Management in Adults With Type 1 Diabetes: a Feasibility Study (D-stress Study)
- Conditions
- Diabetes Type 1
- First Posted Date
- 2025-09-25
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Target Recruit Count
- 110
- Registration Number
- NCT07193446
The Use of Urinary Dickkopf 3 (u DKK3) as a New Biomarker Which Can Identify Patients at High Risk of Renal Allograft Dysfunction, Earlier That the Current Established Tests.
- Conditions
- Renal Transplant Failure
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Target Recruit Count
- 258
- Registration Number
- NCT07176806
- Locations
- 🇬🇧
Guy's and St Thomas' Hospital NHS foundation Trust, London, United Kingdom
- Prev
- 1
- 2
- 3
- 4
- 5
- 55
- Next
News
Brainomix's e-Lung AI Technology Validated for Progressive Pulmonary Fibrosis Detection in Boehringer Ingelheim Collaboration
New studies presented at the American Thoracic Society Conference validate Brainomix's FDA-cleared e-Lung technology as a reliable tool for identifying progressive pulmonary fibrosis with greater sensitivity than conventional methods.
New Bone Marrow Test Could Double Survival Rates for Acute Myeloid Leukemia Patients
A groundbreaking UK trial has developed a highly sensitive bone marrow test that can detect returning Acute Myeloid Leukemia up to three months earlier than standard blood tests, potentially doubling survival rates for some patients.
JAK Inhibitors Reduce Thromboembolic Risk in Myeloproliferative Neoplasms Through Novel Mechanisms
A meta-analysis of 23 publications involving 2,198 patients demonstrated that JAK inhibitors significantly reduce thromboembolic events by 48% in myeloproliferative neoplasm patients, with ruxolitinib showing a 59% reduction in polycythemia vera and myelofibrosis.
Pembrolizumab Shows Promise in Advanced Clear Cell Gynecologic Cancer, PEACOCC Trial Reports
Phase 2 PEACOCC trial demonstrates pembrolizumab's efficacy with 42% disease control rate at 12 weeks in previously treated advanced clear cell gynecologic cancer patients.
Avapritinib Approved for Advanced Systemic Mastocytosis, Offering New Hope to Patients
Avapritinib, a novel drug, has been approved for treating advanced systemic mastocytosis (ASM) by the UK's NICE.